Sensyne, the Oxford-based clinical AI company, has reported total revenues of £ 2.3 million for the six months ended 31 October 2020 and says it as made a strong start to the New Year and are well placed to build on this momentum in 2021.
Lord (Paul) Drayson, CEO of Sensyne Health, said: “I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
“In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States.”
Sensyne has grown its anonymised NHS patient dataset to 6.8 million records, has reached strategic research agreements with Somerset, Hampshire, Milton Keynes University and Royal Wolverhampton NHS Trusts signed between October 2020 and January 2021 to provide access to an aggregate of 2.95 million records and agreed data access with NHS Greater Glasgow and Clyde NHS Trust to provide access to 1.1m anonymised patient datasets in three specific disease areas including cardiovascular disease signed in October 2020
It has also reached a number of commercial agreements within the pharmaceutical industry and launched the SENSE™ clinical algorithm platform to provide real-time clinical decision and operational support.
The £27.5 million fundraise post period end in January 2021 is expected to enable the Group to industrialise its data analytics capability, enter into an exclusive strategic collaboration with Phesi and strengthen its balance sheet for future partnering discussions